Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cleveland Medical Devices has received $1.5 million in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke for further development and clinical validation of Kinesia, a quantitative motor assessment system for evaluating Parkinson's disease symptom severity.
Subscribe to our email newsletter
The initiative includes a large multi-center clinical trial with University Hospitals of Cleveland, the University of Cincinnati, and the Clinical Neuroscience Center in Detroit, Michigan as the participating centers. The trial will aid in development of Kinesia for continuous symptom monitoring in patients’ homes, as well as further validate the correlation between the device and the Unified Parkinson’s Disease Rating Scale (UPDRS).
Kinesia is a compact lightweight system worn on a patient’s wrist and hand that monitors three-dimensional motion and electrical muscle activity (EMG) to objectively quantify the severity of Parkinson’s disease symptoms, such as tremor, bradykinesia (slowed movements) and dyskinesias (wild, involuntary movements).
Joseph Giuffrida, director of CleveMed’s division of movement disorders, said: “This funding will be used to upgrade the system for home use, further validate correlations between Kinesia and the UPDRS and demonstrate efficacy of home monitoring over longer periods of time, such as days, weeks or months, instead of just the snapshot that clinicians see in a typical office exam.”